Literature DB >> 33141245

COVID-19: what the clinician should know about post-mortem findings.

Danny Jonigk1,2, Bruno Märkl3, Julie Helms4,5.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33141245      PMCID: PMC7608308          DOI: 10.1007/s00134-020-06302-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
As of September 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to over 33 million infections and 1.000.000 deaths worldwide [1]. Compared to other coronavirus outbreaks (SARS-CoV-1, MERS-CoV), SARS-CoV-2 is characterized by a higher basic reproductive rate and an overall lower mortality [2]. However, while coronavirus disease 2019 (COVID-19) typically begins as an infection of the upper aerodigestive tract, it may progress to severe forms, with an acute respiratory distress syndrome (ARDS) and a multisystemic disease. COVID-19 ARDS shares the common histological hallmarks with other infectious/non-infectious ARDS. Unspecific diffuse alveolar damage (DAD), as its histologic correlate, is characterized by edema, hemorrhage and intra-alveolar fibrin deposition, but in case of COVID-19 ARDS, also by a distinct angiocentric lymphocytic inflammation [3-5]. DAD is the leading pattern of lung injury and has been shown to be independent of mechanical ventilation. There is some evidence for alternative injury patterns in COVID-19 ARDS, such as acute fibrinous organizing pneumonia (AFOP). Nonetheless, COVID-19-induced DAD is by far the most frequently reported one and is also characterized by more distinct morphologic features, including vascular changes [5]. In that, the detection of SARS-CoV-2 in multiple organs (respiratory tract, heart, endothelium, digestive tract, kidneys, brain) and multisystemic clinical features, suggest that COVID-19 might be a systemic “vascular disease” (Fig. 1). The vasculature indeed appears to be more than a mere means of virus propagation. After virus respiratory tract invasion, the cytokine storm secondary to the innate and adaptive immune responses, along with a potential direct cytopathic effect of the virus, are likely to trigger an endothelial dysfunction [6, 7]. SARS-CoV-2 thus leads to three distinctive angiocentric features with: i. endothelial damage associated with intracellular SARS-CoV-2 virus, platelet activation, elevated D-dimers and fibrinogen; ii. widespread vascular thrombosis, and iii. abnormal vascular architecture (intussusceptive neoangiogenesis), suggesting microangiopathy [8] and resulting in disrupted laminar blood flow and vasoconstriction. This special form of vascularization is thought to act as an aberrant reaction to the viral aggression [4, 9]. The extensive endothelial damage seen in postmortem examinations also suggested viral inclusions being critically involved, but also endothelial inflammation with mononuclear cell infiltrate and lymphocytic endotheliitis, which may account not only for pulmonal damage but for the systemic impaired microcirculatory function in lung, kidney, liver, heart, small intestine in most severe forms of COVID-19 with subsequent organ dysfunction (supplementary figure) [7]. Deep vein thrombosis and pulmonary thromboembolism are one of the most severe consequences of this vascular disease. On the other hand, hemorrhagic colitis, an under-recognized COVID-19 complication, may occur due to microangiopathy of the intestinal vasculature [10].
Fig. 1

This figure illustrates the frequently identified alterations by autopsy in the different organ systems. Following the hypothesis of a vascular driven disease many of those changes are caused by vascular injury due to a viral-induced inflammatory process. Of note, many of those alterations are found in different situation of critical illness as well and not necessarily caused by the direct interaction with the virus. Yellow arrows indicate proinflammatory cytokines

This figure illustrates the frequently identified alterations by autopsy in the different organ systems. Following the hypothesis of a vascular driven disease many of those changes are caused by vascular injury due to a viral-induced inflammatory process. Of note, many of those alterations are found in different situation of critical illness as well and not necessarily caused by the direct interaction with the virus. Yellow arrows indicate proinflammatory cytokines Noteworthy, cardiac involvement does not involve the classic morphologic features of viral myocarditis. SARS-CoV-2 detection is rare and, therefore, a damage similar to the lungs is unlikely. Indeed, cardiac histopathological findings combine inflammatory and prothrombotic features, with rather mild epicardial inflammation and mononuclear infiltrate, with local occasional small vessel thrombi, congestive cardiomyopathy, and a few cases of focal lymphocytic myocarditis. Other findings, however, are attributed to prior conditions, like atherosclerotic coronary artery disease, chronic ischemic cardiomyopathy, myocardial hypertrophy [6, 11, 12]. Beside respiratory manifestations, up to 30% of the patients with COVID-19 may develop acute kidney injury. Postmortem findings mainly revealed morphological hallmarks of extensive acute tubular damage and necrosis, with marked degenerative changes and glomerulopathy appearing to be in line with other viral infections of the kidney [6, 13, 14]. Other autopsy findings included arterionephrosclerosis, extensive degenerative changes, focal segmental glomerulosclerosis and hypertensive changes in most patients (80%) [4]. Similarly, most severe patients with COVID-19 also frequently develop moderate disturbed liver and pancreatic functions. However, both damages are nonspecific and more likely to be due to the critical illness or pre-existing disease. Liver damages indeed mainly consisted of cirrhosis and steatosis, sinusoidal congestion and dilation, lobular lymphocytic infiltrates, hepatitis, necrosis, venous obstruction, thrombi and hemophagocytosis [4, 6]. Hemophagocytosis, mainly lymphophagocytosis was also identified within the lymph nodes, bone marrow, and spleen [4, 6]. Finally, a bundle of evidence has assessed the neurotropism and neurological injury caused by SARS-CoV-2, although the multiple pathways to access the central nervous system (CNS) in COVID-19 patients are unknown. Ultrastructural analysis autopsy findings of SARS-CoV-2 in the olfactory pathways and brainstem have shown that SARS-CoV-2 may also reach the CNS, from the nasal mucosa to the olfactory bulb via the cribriform plate and be transported by the cerebrospinal fluid to the adjacent and distant areas of the CNS. Indeed, SARS-CoV-2 virion particles have been reported in the neurons, glia, nerve axons, and myelin sheath, and widespread tissue damage have been described by Bulfamante et al. [15]. Other authors, however, identified only weak alterations of the CNS with no or infrequent direct virus detection in the nervous parenchyma and cerebrospinal fluid [11, 16]. Other histopathological findings in the central nervous system are similar to those of other organs and include vascular abnormalities with widespread microthrombi, ischemic necrosis, vascular edema, and dotted subarachnoid hemorrhages [4, 6]. Pooling data of different studies to build larger series and minute histological work up as well as multi-omics analyses with radiological correlation will eventually lead to distinguishing between well-known alterations in other situations of critical illness and COVID-19-specific structural and functional changes. Our understanding of how the virus spreads within patients, as well as how organs undergo molecular alterations remains very limited. Variability in post-mortem examination in the early epidemics, due to the lack of appropriate biosafety conditions and/or personal protective equipment, has led to still partial findings. However, recommendations have now been published to minimize the risk of infection transmission to the employees; to our best knowledge only one infection attributable to exposure during autopsy has been published. Although autopsy-based findings mainly provide information about late stages of the disease, it appears essential to understand the discrepancies between clinical presentation and actual organ involvement. Autopsy findings have contributed to a better comprehension of the disease and therapeutic evolution since the beginning of the epidemic. Such findings have led to an understanding of the need for prevention from thrombotic events and downregulation of the immunogenic response (supplementary table). Further advances may help personalize therapy by identification of different disease types. A strong physician family relationship is the basis for receiving autopsy consent. Careful guidance of the relatives is mandatory but also a challenging task, especially for younger physicians. However, hereby contributing to medical knowledge will help future patients and can comfort grieving relatives. More autoptic data are needed to confirm certain findings and perhaps identify relations between different strains and disease progression. Below is the link to the electronic supplementary material. Supplementary file1 (TIFF 14826 kb) a. Autopsy specimen with a complete thrombotic occlusion of the left renal vein by a large thrombus from the inferior vena cava (Augsburg series). b. COVID-19 lung with diffuse alveolar damage (DAD) as the histological hallmark of acute respiratory distress syndrome (ARDS). Note the heterogeneously distributed interstitial inflammatory cells, detritus and edema. The alveolar cells are lined by superimposed hyaline membranes (original magnification x200; tissue specimen by courtesy of Petra Jasker, Institute for Pathology und Dermatology, Düsseldorf, Germany). c. Scanning electron microscopy image of a pulmonary COVID-19 specimen with ARDS / DAD. In the alveolar lumina, the epithelium is almost completely covered by hyaline membranes, which inhibit pulmonary gas exchange (scale bar indicates 100 µm; picture by courtesy of Maximilian Ackermann, Institute of Functional and Clinical Anatomy, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany). d. COVID-19 lung with cytoplasmic granular staining by RNA-scope technique (original magnification x630; Augsburg series). Supplementary file2 (DOCX 15 kb)
  15 in total

1.  Histopathologic and Ultrastructural Findings in Postmortem Kidney Biopsy Material in 12 Patients with AKI and COVID-19.

Authors:  Pouneh Golmai; Christopher P Larsen; Maria V DeVita; Samuel J Wahl; Astrid Weins; Helmut G Rennke; Vanesa Bijol; Jordan L Rosenstock
Journal:  J Am Soc Nephrol       Date:  2020-07-16       Impact factor: 10.121

2.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.

Authors:  Maximilian Ackermann; Stijn E Verleden; Mark Kuehnel; Axel Haverich; Tobias Welte; Florian Laenger; Arno Vanstapel; Christopher Werlein; Helge Stark; Alexandar Tzankov; William W Li; Vincent W Li; Steven J Mentzer; Danny Jonigk
Journal:  N Engl J Med       Date:  2020-05-21       Impact factor: 91.245

3.  Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series.

Authors:  Benjamin T Bradley; Heather Maioli; Robert Johnston; Irfan Chaudhry; Susan L Fink; Haodong Xu; Behzad Najafian; Gail Deutsch; J Matthew Lacy; Timothy Williams; Nicole Yarid; Desiree A Marshall
Journal:  Lancet       Date:  2020-07-16       Impact factor: 79.321

4.  Endothelial cell infection and endotheliitis in COVID-19.

Authors:  Zsuzsanna Varga; Andreas J Flammer; Peter Steiger; Martina Haberecker; Rea Andermatt; Annelies S Zinkernagel; Mandeep R Mehra; Reto A Schuepbach; Frank Ruschitzka; Holger Moch
Journal:  Lancet       Date:  2020-04-21       Impact factor: 79.321

5.  Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.

Authors:  George Goshua; Alexander B Pine; Matthew L Meizlish; C-Hong Chang; Hanming Zhang; Parveen Bahel; Audrey Baluha; Noffar Bar; Robert D Bona; Adrienne J Burns; Charles S Dela Cruz; Anne Dumont; Stephanie Halene; John Hwa; Jonathan Koff; Hope Menninger; Natalia Neparidze; Christina Price; Jonathan M Siner; Christopher Tormey; Henry M Rinder; Hyung J Chun; Alfred I Lee
Journal:  Lancet Haematol       Date:  2020-06-30       Impact factor: 18.959

6.  Coronavirus disease 2019 (COVID-19) and ischemic colitis: An under-recognized complication.

Authors:  Kok Hoe Chan; Su Lin Lim; Ahmad Damati; Siva Prasad Maruboyina; Leena Bondili; Amany Abu Hanoud; Jihad Slim
Journal:  Am J Emerg Med       Date:  2020-05-27       Impact factor: 2.469

7.  Tubuloreticular inclusions in COVID-19-related collapsing glomerulopathy.

Authors:  François Gaillard; Sophie Ismael; Aurélie Sannier; Hassan Tarhini; Thomas Volpe; Clarisse Greze; Marie Christine Verpont; Ilyass Zouhry; Christophe Rioux; François-Xavier Lescure; David Buob; Eric Daugas
Journal:  Kidney Int       Date:  2020-04-27       Impact factor: 10.612

8.  Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study.

Authors:  Dominic Wichmann; Jan-Peter Sperhake; Marc Lütgehetmann; Stefan Steurer; Carolin Edler; Axel Heinemann; Fabian Heinrich; Herbert Mushumba; Inga Kniep; Ann Sophie Schröder; Christoph Burdelski; Geraldine de Heer; Axel Nierhaus; Daniel Frings; Susanne Pfefferle; Heinrich Becker; Hanns Bredereke-Wiedling; Andreas de Weerth; Hans-Richard Paschen; Sara Sheikhzadeh-Eggers; Axel Stang; Stefan Schmiedel; Carsten Bokemeyer; Marylyn M Addo; Martin Aepfelbacher; Klaus Püschel; Stefan Kluge
Journal:  Ann Intern Med       Date:  2020-05-06       Impact factor: 25.391

9.  Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients.

Authors:  Myriam Remmelink; Ricardo De Mendonça; Nicky D'Haene; Sarah De Clercq; Camille Verocq; Laetitia Lebrun; Philomène Lavis; Marie-Lucie Racu; Anne-Laure Trépant; Calliope Maris; Sandrine Rorive; Jean-Christophe Goffard; Olivier De Witte; Lorenzo Peluso; Jean-Louis Vincent; Christine Decaestecker; Fabio Silvio Taccone; Isabelle Salmon
Journal:  Crit Care       Date:  2020-08-12       Impact factor: 9.097

10.  Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model.

Authors:  Barry Rockx; Thijs Kuiken; Sander Herfst; Theo Bestebroer; Mart M Lamers; Bas B Oude Munnink; Dennis de Meulder; Geert van Amerongen; Judith van den Brand; Nisreen M A Okba; Debby Schipper; Peter van Run; Lonneke Leijten; Reina Sikkema; Ernst Verschoor; Babs Verstrepen; Willy Bogers; Jan Langermans; Christian Drosten; Martje Fentener van Vlissingen; Ron Fouchier; Rik de Swart; Marion Koopmans; Bart L Haagmans
Journal:  Science       Date:  2020-04-17       Impact factor: 47.728

View more
  19 in total

Review 1.  Pulmonary and Systemic Pathology in COVID-19.

Authors:  Danny Jonigk; Christopher Werlein; Peter D Lee; Hans-Ulrich Kauczor; Florian Länger; Maximilian Ackermann
Journal:  Dtsch Arztebl Int       Date:  2022-06-24       Impact factor: 8.251

2.  Characteristics and outcomes of Behçet's syndrome patients with Coronavirus Disease 2019: a case series of 10 patients.

Authors:  Berna Yurttaş; Mert Oztas; Ali Tunc; İlker İnanç Balkan; Omer Fehmi Tabak; Vedat Hamuryudan; Emire Seyahi
Journal:  Intern Emerg Med       Date:  2020-07-09       Impact factor: 3.397

3.  Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy.

Authors:  Federica Melazzini; Marta Colaneri; Federica Fumoso; Giulia Freddi; Marco Vincenzo Lenti; Teresa Chiara Pieri; Davide Piloni; Patrizia Noris; Carla Pieresca; Paola Stefania Preti; Mariaconcetta Russo; Angelo Corsico; Guido Tavazzi; Fausto Baldanti; Antonio Triarico; Francesco Mojoli; Raffaele Bruno; Antonio Di Sabatino
Journal:  Intern Emerg Med       Date:  2020-11-08       Impact factor: 3.397

4.  Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study.

Authors:  Julie Helms; François Severac; Hamid Merdji; Maleka Schenck; Raphaël Clere-Jehl; Mathieu Baldacini; Mickaël Ohana; Lélia Grunebaum; Vincent Castelain; Eduardo Anglés-Cano; Laurent Sattler; Ferhat Meziani
Journal:  Ann Intensive Care       Date:  2021-01-25       Impact factor: 6.925

5.  Is the mechanism of COVID-19 coagulopathy still a rabbit's hole?

Authors:  Ashna Rajan; Ganesh Keshav Thirunavukkarasu; Richard F Lockey; Narasaiah Kolliputi
Journal:  J Cell Commun Signal       Date:  2021-06-02       Impact factor: 5.782

6. 

Authors:  N Taghboulit; G Voiriot; A Demoule; J Helms
Journal:  Rev Malad Respir Actual       Date:  2021-06-25

7.  Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19.

Authors:  Sven Maier; Dawid L Staudacher; Xavier Bemtgen; Viviane Zotzmann; Christoph Benk; Jonathan Rilinger; Katrin Steiner; Alexander Asmussen; Christoph Bode; Tobias Wengenmayer
Journal:  J Thromb Thrombolysis       Date:  2021-02       Impact factor: 2.300

8.  Combining lung ultrasound and Wells score for diagnosing pulmonary embolism in critically ill COVID-19 patients.

Authors:  Viviane Zotzmann; Corinna N Lang; Tobias Wengenmayer; Xavier Bemtgen; Bonaventura Schmid; Katharina Mueller-Peltzer; Alexander Supady; Christoph Bode; Daniel Duerschmied; Dawid L Staudacher
Journal:  J Thromb Thrombolysis       Date:  2020-11-03       Impact factor: 2.300

Review 9.  COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects.

Authors:  David M Smadja; Steven J Mentzer; Michaela Fontenay; Mike A Laffan; Maximilian Ackermann; Julie Helms; Danny Jonigk; Richard Chocron; Gerald B Pier; Nicolas Gendron; Stephanie Pons; Jean-Luc Diehl; Coert Margadant; Coralie Guerin; Elisabeth J M Huijbers; Aurélien Philippe; Nicolas Chapuis; Patrycja Nowak-Sliwinska; Christian Karagiannidis; Olivier Sanchez; Philipp Kümpers; David Skurnik; Anna M Randi; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2021-06-28       Impact factor: 9.596

10.  Extracorporeal membrane oxygenation for respiratory failure in COVID-19 patients: outcome and time-course of clinical and biological parameters.

Authors:  Pierre Huette; Christophe Beyls; Mathieu Guilbart; Alexandre Coquet; Pascal Berna; Guillaume Haye; Pierre-Alexandre Roger; Patricia Besserve; Michael Bernasinski; Hervé Dupont; Osama Abou-Arab; Yazine Mahjoub
Journal:  Can J Anaesth       Date:  2020-06-01       Impact factor: 6.713

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.